Expression of immunoreactive inducible nitric oxide synthase in pancreatic islet cells from newly diagnosed and long-term type 1 diabetic donors is heterogeneous and not disease-associated

Reddy, Shiva; Krogvold, Lars; Martin, Charlton; Sun, Kevin; Martin, Owen; Al-Ani, Aamenah; Dahl‐Jørgensen, Knut

doi:10.1007/s00441-020-03340-4

Cited by 4 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We mentioned above that NO and iNOS are involved in the effects of IFN-γ, TNF-α, and IL-1β on pancreatic β-cells, and that DRAK2 is also involved in between. Some studies have identified the specific mechanisms involved in these effects ( Reddy et al, 2021 ). This process is associated with the activation of the nuclear factor (NF)-kb signaling pathway by IL-1β and the expression of iNOS ( Figure 5 ).…”

Section: The Upstream Pathways Of Drak2mentioning

confidence: 99%

New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential

Zheng

Kuang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

As a member of the death-associated protein kinase (DAPK) family, DAP kinase-associated apoptosis-inducing kinase 2 (DRAK2) performs apoptosis-related functions. Compelling evidence suggests that DRAK2 is involved in regulating the activation of T lymphocytes as well as pancreatic β-cell apoptosis in type I diabetes. In addition, DRAK2 has been shown to be involved in the development of related tumor and non-tumor diseases through a variety of mechanisms, including exacerbation of alcoholic fatty liver disease (NAFLD) through SRSF6-associated RNA selective splicing mechanism, regulation of chronic lymphocytic leukemia and acute myeloid leukemia, and progression of colorectal cancer. This review focuses on the structure, function, and upstream pathways of DRAK2 and discusses the potential and challenges associated with the clinical application of DRAK2-based small-molecule inhibitors, with the aim of advancing DRAK2 research.

show abstract

Section: The Upstream Pathways Of Drak2mentioning

confidence: 99%